INNOVA CAPTAB
|
The Current P/E Ratio of INNOVA CAPTAB is 35.74.
| Share Price | ₹880.5 | May 20,2026 |
| Market Cap | ₹5,036.2 Cr | |
| Earnings-TTM | ₹140.9 Cr | TTM-Consolidated Results |
| Price/Earnings | 35.74x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of INNOVA CAPTAB
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹5,036.2 Cr] as on May 20,2026
(/) Earnings [ ₹140.9 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 35.74x ]
Thus, for INNOVA CAPTAB , the investors are currently willing to pay 35.74 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of INNOVA CAPTAB !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of INNOVA CAPTAB over the last five years.
Historical PE (Price/Earnings) ratio chart of INNOVA CAPTAB
PE Ratio Performance Analysis for INNOVA CAPTAB
- INNOVA CAPTAB 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 13.27x.
- INNOVA CAPTAB 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, INNOVA CAPTAB 's p/e ratio peaked in Mar2025 at 39.15x.
- INNOVA CAPTAB 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does INNOVA CAPTAB 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| INNOVA CAPTAB | 140.92 | 35.74 | 5,036.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 41.01 | 451,195.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 73.82 | 182,993.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 65.99 | 149,926.0 |
| CIPLA LTD | 3,869.79 | 29.21 | 113,052.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 26.62 | 110,333.0 |
| MANKIND PHARMA LTD | 1,926.41 | 55.37 | 106,669.0 |
| LUPIN LTD | 5,355.47 | 19.49 | 104,401.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 20.84 | 104,744.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 24.86 | 87,336.6 |
| LAURUS LABS LTD | 889.85 | 82.59 | 73,490.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs INNOVA CAPTAB 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 19.49x |
| Max industry PE | 82.59x |
| Median industry PE | 35.74x |
| Average industry PE | 43.23x |
You may also like the below Video Courses